Drug Profile
Research programme: peptide conjugate therapeutics - Esperance
Alternative Names: EP-302Latest Information Update: 28 May 2019
Price :
$50
*
At a glance
- Originator Esperance Pharmaceuticals
- Class Antineoplastics; Peptides
- Mechanism of Action Cell membrane permeability enhancers; Cell membrane structure modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2019 No recent reports of development identified for preclinical development in Cancer in USA (IV, Injection)
- 11 May 2017 Preclinical development is ongoing in Cancer in USA (Esperance pipeline, May 2017)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (IV, Injection)